← All trials
NCT04617756
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Jan 1, 2024
- Completion date
- Jun 1, 2024
- First posted
- Nov 5, 2020
- Last posted
- Nov 5, 2020
- Enrollment
- 99
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centre Hospitalier Universitaire de NīmesLead sponsor
- University of ParisCollaborator
- University of ToulouseCollaborator
- University of ParisCollaborator
- University of LyonCollaborator
- Institut Paoli-CalmettesCollaborator
- University of ParisCollaborator
- University of VersaillesCollaborator
- University of RennesCollaborator
- Sorbonne UniversityCollaborator
- hopital rangueilCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.